“We are pleased to advance MLE-301 into clinical development, prioritizing our resources on this valuable asset and leveraging Millendo’s expertise in the NK3R category,” said Julia C. Owens,
Financial details of the transaction were not disclosed. With its unique understanding of the CNS market built over 35 years, Neuraxpharm develops and commercializes value-added medicines and consumer
The late-stage trial called ENSEMBLE to be held in multiple countries across three countries will study the safety and efficacy of a single dosage of JNJ-78436735 in comparison
The study marks the world’s first evaluation of a pharmaceutical endolysin for topical use in humans. Endolysins are highly specific enzymes that cut the bacterial cell wall, rapidly
The companies are seeking approval for the use of ide-cel in adult patients with the disease who have been subjected to least three prior therapies. The investigational cell
In the study, KEYTRUDA in combination with chemotherapy significantly improved overall survival (OS), reducing the risk of death by 27% [HR=0.73 [95% CI, 0.62-0.86]; p<0.0001], versus chemotherapy in
The CheckMate -649 trial demonstrated statistically significant and clinically meaningful improvement in both the parameters for the Opdivo + chemotherapy arm compared to chemotherapy alone. The late-stage trial
Late-breaking, first-time study results showed that with 3.5 years of follow-up, adjuvant KEYTRUDA met the key secondary endpoint of distant metastasis-free survival (DMFS), reducing the risk of distant
The global trial called EV-301 compared PADCEV to chemotherapy in nearly 600 patients who had prior treatment with platinum-based chemotherapy and a PD-1/L1 inhibitor. Co-developed by the two
Since inception in 2017, Eyevance develops and commercializes topical ophthalmic products targeting the ocular surface and anterior segment. Within this area of focus, Eyevance currently offers anti-inflammatory, anti-allergic,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.